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Hyperbilirubinaemia is one of the most frequent problems in otherwise healthy newborn infants. Early discharge of
the healthy newborn infants, particularly those in whom breastfeeding is not fully established, may be associated
with delayed diagnosis of significant hyperbilirubinaemia that has the potential for causing severe neurological
impairments. We present the shared Italian guidelines for management and treatment of jaundice established by
the Task Force on hyperbilirubinaemia of the Italian Society of Neonatology.
The overall aim of the present guidelines is to provide an useful tool for neonatologists and family paediatricians
for managing hyperbilirubinaemia.
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Hyperbilirubinaemia is a very common condition. The
prevention, detection and management of jaundice re-
mains a challenge especially because of early discharge of
healthy late preterm and full term newborn infants [1-3].
Early discharge of the healthy newborn, particularly those
in whom breastfeeding is not fully established, may be as-
sociated with delayed diagnosis of severe hyperbilirubinae-
mia [1,4,5]. A recent survey performed by Dani et al. [6]
showed that the management of hyperbilirubinaemia is
not homogeneous in Italy. Therefore the Task Force on
hyperbilirubinaemia of the Italian Society of Neonatology
drew up national guidelines for management of jaundice
in the newborn and established a national registry of ker-
nicterus and hyperbilirubinaemia in order to monitor the
incidence of cases of kernicterus and severe hyperbilirubi-
naemia in Italy over time.Focus of guidelines
The overall aim of this guidelines is to provide an useful
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article, unless otherwise stated.managing hyperbilirubinaemia. These recommendations
promote an approach based on the importance of uni-
versal systematic assessment for the risk of severe hyper-
bilirubinaemia, close follow-up, and prompt intervention
when indicated. The statement fully applies to the care
of infants at 35 or more weeks of gestation, while only
some recommendations could be used for newborn
infants with lower gestational age (GA).
Methods of statement development
Literature searches were last updated in September 2013.
Guidelines from AAP [7-9], NICE [10,11], Canadian
Pediatric Association [12], Nederland Neonatal Research
Network [13], Norwegian Pediatric Society [14], Israel
[15], New Zealand [16], Australia (Queensland) [17], India
[18], Spain [19], Switzerland [20] were considered. Studies
conducted in the neonatal units of Lazio were also evalu-
ated to obtain recommendations more suitable for Italian
population [21-23].
The hierarchy of evidence from the Centre for
Evidence-Based-Medicine was applied (see Table 1) [24].
Acute bilirubin encephalopathy
The main aim of these guidelines is to avoid cases of acute
bilirubin encephalopathy (ABE) by establishing levels oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 The hierarchy of evidence from the centre for
evidence-based-medicine
Level Definition
1a Systematic review (with homogeneity) of RCTs
1b Individual RCT (with narrow confidence interval)
2a Systematic review (with homogeneity) of cohort studies
2b Individual cohort study
3a Systematic review (with homogeneity) of case–control studies
3b Individual case–control study
4 Case-series (and poor quality cohort and case–control studies)
5 Expert opinion without explicit critical appraisal, or
based on physiology, bench research or “first principles”
Table 2 Values of TcB corresponding at the 50th and
75th percentile of the hour-specific nomogram
h 50th 75th h 50th 75th h 50th 75th
24 6, 3 7, 8 49 7, 7 10, 4 73 10 11, 7
25 6, 3 7, 8 50 7, 8 10, 4 74 10 11, 8
26 6, 4 7, 8 51 8 10, 5 75 10, 1 11, 9
27 6, 4 7, 9 52 8, 1 10, 5 76 10, 1 11, 9
28 6, 4 7, 9 53 8, 3 10, 6 77 10, 2 12
29 6, 5 7, 9 54 8, 4 10, 6 78 10, 2 12, 1
30 6, 5 7, 9 55 8, 6 10, 7 79 10, 3 12, 2
31 6, 6 8, 1 56 8, 7 10, 8 80 10, 4 12, 2
32 6, 6 8, 4 57 8, 9 11 81 10, 5 12, 3
33 6, 7 8, 6 58 9 11, 1 82 10, 5 12, 3
34 6, 7 8, 8 59 9, 2 11, 2 83 10, 6 12, 4
35 6, 8 9, 1 60 9, 3 11, 3 84 10, 7 12, 4
36 6, 8 9, 3 61 9, 4 11, 3 85 10, 7 12, 4
37 6, 9 9, 4 62 9, 5 11, 4 86 10, 8 12, 4
38 7, 1 9, 5 63 9, 6 11, 4 87 10, 8 12, 4
39 7, 2 9, 7 64 9, 6 11, 4 88 10, 8 12, 4
40 7, 3 9, 8 65 9, 7 11, 5 89 10, 9 12, 4
41 7, 5 9, 9 66 9, 8 11, 5 90 10, 9 12, 4
42 7, 5 10 67 9, 8 11, 5 91 10, 9 12, 5
43 7, 5 10, 1 68 9, 8 11, 5 92 10, 9 12, 5
44 7, 6 10, 1 69 9, 9 11, 6 93 10, 9 12, 6
45 7, 6 10, 2 70 9, 9 11, 6 94 10, 9 12, 6
46 7, 6 10, 2 71 9, 9 11, 6 95 10, 9 12, 7
47 7, 6 10, 3 72 9, 9 11, 6 96 10, 9 12, 7
48 7, 6 10, 3
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bilirubin (TSB) of 20 mg/dl should not be exceeded in the
first 96 hours of life in term newborns. After 96 hours of
life a TSB of 25 mg/dl should be avoided (evidence level
2b), since the efficacy of Blood–brain-Barrier increases with
postnatal age. The safe bilirubin level is lower for preterm
infants: 12 mg/dl for babies with GA ≤ 30 weeks and
15 mg/dL for babies with GA 31–36 weeks [25,26].
Apart from TSB level, gestational age and postnatal age,
some more risk factors for ABE should also be considered:
 Birth asphyxia
 Severe hypothermia (Tc < 36°C for > 6 hours)
 Respiratory failure (RDS, pneumonia, meconium
aspiration syndrome)
 Prolonged acidosis (pH < 7.20 for > 6 hours)
 Severe hypoglycaemia (glucose < 45 mg/dl for >
12 hours)
 Severe haemolysis
 Sepsis and meningitis
 Drugs impairing bilirubin/albumin binding
Bilirubin measurement
All infants should be routinely monitored for the devel-
opment of jaundice. The ability of physicians and other
health care providers to recognise clinically significant
jaundice and predict bilirubin levels based on the
coephalo-caudal progression of jaundice is limited (evi-
dence level 1b) [27-31].
Therefore each jaundiced newborn should receive a
bilirubin measurement. Transcutaneous bilirubin (TcB)
can be used as first step in order to reduce the number of
invasive and painful blood sampling. BiliCheck TM
(Respironics, Marietta, GA – USA) and JM-103 (Drager
Medical Inc, Telford, Pennsylvania) are the two most used
bilirubinometers in the studies conducted in the Italian
population and both had good correlation with TSB values
[21,22,32,33]. TSB measurement is always necessary when
the level of bilirubin is high and for therapeutic decisions
(evidence level 1b).Prediction of hyperbilirubinaemia
The evaluation of jaundice is now facilitated by the avail-
ability of different nomograms for both serum [34] and
transcutaneous bilirubin [21,35,36]. However, a nomogram
could not perform well in one specific setting if the racial,
genetic and environmental background of that setting are
too different from that of the reference population.
Furthermore, predictive tools should be developed in one
sample and validated in another one. Hour-specific per-
centile based nomograms have been developed in cohorts
of healthy Italian full term neonates or Italian neonates
with ≥ 35 weeks’ gestational age using serial measurements
of TcB and TSB (Tables 2 and 3; Figures 1 and 2) [21,23].
In a second phase the predictive ability of these nomograms
has been evaluated. Sensitivity, specificity, positive and
negative predictive value of percentiles in predicting signifi-
cant hyperbilirubinaemia (defined as TSB > 17 mg/dL or
need for phototherapy) are listed in Tables 4 and 5.
On the base of these studies the Task Force on hyper-
bilirubinaemia of the Italian Society of Neonatology
Table 3 Values of TSB corresponding at the 50th, 75th
and 90th percentile of the hour-specific nomogram
h 50th 75th 90th h 50th 75th 90th h 50th 75th 90th
24 6.1 7.5 8.9 49 9.0 10.3 11.9 73 10.0 11.7 13.2
25 6.2 7.7 9.1 50 9.1 10.4 12.0 74 10.0 11.8 13.3
26 6.4 7.8 9.2 51 9.1 10.4 12.1 75 10.1 11.8 13.3
27 6.5 8.0 9.3 52 9.2 10.5 12.2 76 10.1 11.8 13.4
28 6.7 8.2 9.5 53 9.2 10.6 12.3 77 10.2 11.9 13.4
29 6.8 8.3 9.6 54 9.3 10.7 12.4 78 10.2 11.9 13.5
30 7.0 8.5 9.7 55 9.3 10.8 12.5 79 10.3 12.0 13.5
31 7.2 8.6 9.9 56 9.3 10.8 12.5 80 10.3 12.1 13.6
32 7.3 8.7 10.1 57 9.3 10.9 12.6 81 10.4 12.1 13.7
33 7.5 8.9 10.2 58 9.4 10.9 12.7 82 10.5 12.2 13.7
34 7.7 9.0 10.5 59 9.4 11.0 12.8 83 10.6 12.3 13.8
35 7.9 9.1 10.6 60 9.5 11.0 12.9 84 10.6 12.4 13.8
36 8.0 9.2 10.8 61 9.5 11.1 12.9 85 10.6 12.4 13.9
37 8.1 9.3 10.8 62 9.5 11.1 12.9 86 10.7 12.5 14.0
38 8.2 9.4 10.9 63 9.5 11.2 12.9 87 10.7 12.5 14.1
39 8.3 9.5 10.9 64 9.6 11.2 13.0 88 10.7 12.5 14.2
40 8.4 9.6 11.0 65 9.6 11.3 13.0 89 10.8 12.6 14.3
41 8.5 9.7 11.1 66 9.6 11.3 13.0 90 10.8 12.6 14.4
42 8.6 9.8 11.1 67 9.6 11.4 13.0 91 10.9 12.7 14.5
43 8.7 9.9 11.2 68 9.6 11.4 13.1 92 11.0 12.9 14.6
44 8.7 9.9 11.3 69 9.7 11.5 13.1 93 11.2 13.0 14.7
45 8.8 10.0 11.5 70 9.8 11.6 13.1 94 11.3 13.2 14.8
46 8.9 10.1 11.6 71 9.8 11.7 13.2 95 11.4 13.4 14.9
47 8.9 10.2 11.7 72 9.9 11.7 13.2 96 11.5 13.5 15.0
48 9.0 10.2 11.8
Figure 1 Depicts hour-specific percentile based nomograms for TcB.
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GA ≥ 35 weeks (evidence level 1b).
Recommendations:
 All jaundiced newborn infants should be tested with
a TcB measurement and the value should be plotted
on the hour-specific nomogram for TcB measure-
ments (Table 2).
 If the TcB measurement is > 75th percentile, a serum
determination of bilirubin should be performed and
the value should be plotted on the nomogram for
TSB measurements (Table 3).
 Newborn infants with a TSB value < 50th percentile in
the first 48 hours of live and babies with a value < 75th
percentile after 48 hours of life are not at risk of
hyperbilirubinaemia and do not require further
evaluations.
 Newborn infants with a TSB value > 50th percentile in
the first 48 hours of live and babies with a value >
75th percentile after 48 hours of life are at risk of
hyperbilirubinaemia and should be tested again after
24 or 48 hours according to the hours of life and the
presence of clinical risk factors.
At present, there are no nomograms able to predict
hyperbilirubinaemia in infants with GA< 35 weeks. There-
fore bilirubin measurements should be decided according
to GA and treatment thresholds (evidence level 5).
Treatment: phototherapy
There is no reliable evidence to inform the choice of
thresholds for starting phototherapy. For this reasons guide-
lines report different recommendations. In determining the
Figure 2 Depicts hour-specific percentile based nomograms for TSB.
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Neonatology considered as primary aim to choose a thresh-
old allowing a large margin of safety, being the threshold
for starting phototherapy less than that for performing ex-
change transfusion, and not so low to become unnecessary.
The thresholds for phototherapy are showed in a graph
in which total bilirubin is plotted against age in hours. The
groups of GA (GA < 30; 30–31; 32–34; 35–37; > 37) are
represented by different lines (Figure 3).
Recommendations:
 Phototherapy should be administered for irradiating
the most of the infant’s skin.Table 4 Ability of TcB measurements over the 50th, the 75th an
significant hyperbilirubinaemia, for designated time periods
Hours of life TP FN TN FP
24 - 48 hours
<50th percent 27 0 161 460
<75th percent 25 2 429 192
<90th percent 14 13 564 57
49 - 72 hours
<50th percent 21 0 410 615
<75th percent 21 0 702 323
<90th percent 18 3 888 137
73 - 96 hours
<50th percent 7 0 246 220
<75th percent 7 0 348 118
<90th percent 5 2 409 57 Intensive phototherapy with an irradiance > 35 μW/
cm2/nm is recommended. Daylight, blue light,
conventional or blue LED phototherapy can be used
(evidence level 1a).
 Fiberoptic phototherapy can be used even if it is less
effective than conventional phototherapy and require
more prolonged treatment (evidence level 1a) [37].
 Serum bilirubin should be tested 4–8 hours after the
beginning of phototherapy or earlier if TSB < 3 mg/dL
less than threshold for exchange transfusion.
Subsequently, TSB should be assessed every 12–
24 hours to monitor the treatment effectiveness.
 In case of treatment failure, multiple phototherapy
should be started adding a fiberoptic device to thed the 90th percentile of TcB nomogram to predict
Sensitivity Specificity PPV NPV
100% 25.9% 5.5% 100%
92.6% 69.1% 11.5% 99.5%
51.9% 90.8% 19.7% 97.7%
100% 40% 3.3% 100%
100% 68.5% 6.1% 100%
85.7% 86.6 11.6% 99.7%
100% 52.8% 3.1% 100%
100% 74.7% 5.6% 100%
71.4% 87.8% 8.1% 99.5%
Table 5 Ability of TSB measurements over the 50th, the 75th and the 90th percentile of TSB nomogram to predict
significant hyperbilirubinaemia, for designated time periods
Hours of life TP FN TN FP Sensitivity Specificity PPV NPV
24 - 48 hours
<50th percent 24 1 357 263 96.0% 57.6% 8.4% 99.7%
<75th percent 22 3 479 141 88.0% 77.3% 13.5% 99.4%
<90th percent 12 13 576 44 48.0% 92.9% 21.4% 97.8%
49 - 72 hours
<50th percent 23 0 657 368 100% 64.1% 5.9% 100%
<75th percent 22 1 860 165 95.7% 83.9% 11.8% 99.9%
<90th percent 17 6 975 50 73.9% 95.1% 25.4% 99.4%
73 - 96 hours
<50th percent 7 0 322 145 100% 69.0% 4.6% 100%
<75th percent 7 0 409 58 100% 87.6% 10.8% 100%
<90th percent 6 1 446 21 85.7% 95.5% 22.2% 99.8%
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exposure (evidence level 1a) [37].
 Phototherapy should be discontinued once the
bilirubin levels are below the threshold value for
treatment on two consecutive measurements,
6–12 h apart. This would avoid keeping babies
under phototherapy longer than necessary [38]
(evidence level 1b).
 Serum bilirubin should be checked 12–24 hours
after discontinuation of phototherapy the
occurrence of post-phototherapy bilirubin rebound
[39] (evidence level 4).
 Infants with either Rhesus or ABO haemolytic
disease should be immediately treated with
phototherapy once the diagnosis is made.Figure 3 The graph shows the thresholds for phototherapy. Total bilir
represented with different lines.Hydration status should be monitored during photo-
therapy by daily weighing of the baby, assessing wept
nappies and, if required, monitoring electrolytaemia.
Breastfeeding should not be discontinued, because its
interruption is associated with an increased frequency
of stopping breastfeeding by one month (evidence level
2b) [40]. Italian Society of Neonatology suggests brief
suspensions (up to 30 minutes) of phototherapy for
allowing breastfeeding.
Breastfed babies should not be routinely supplemented
with formula, water or dextrose water for the treatment of
jaundice (evidence level 1b) [7,41]. The need for additional
fluids during phototherapy should be considered only
when the daily weight loss is higher then 5%, or when
breast milk is not sufficient to permit the full feeding.ubin was plotted against age in hours. The groups of GA were
Figure 4 The graph shows the thresholds for exchange transfusion. Total bilirubin was plotted against age in hours. The groups of GA were
represented with different lines.
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Exchange Transfusion is recommended for newborn infants
with TSB levels at risk of neurologic damage and with clin-
ical signs and symptoms of ABE. However, available guide-
lines suggest different thresholds for ET, without differences
between haemolytic and non haemolytic jaundice.
TSB threshold for ET in newborns with non haemo-
lytic jaundice are generally 5–6 mg/dL higher than TSB
threshold for phototherapy (Figure 4).
The TSB threshold for ET in newborns with Rh or
ABO haemolytic jaundice is lower than that of newborns
with non haemolytic jaundice (Figure 5).
The more conservative approach to the treatment of
ABO haemolytic disease compared to Rh haemolytic
disease is due to its less aggressive development.Figure 5 The graph shows the thresholds for exchange transfusion in
in hours.Recommendations (see Additional file 1):
 ET should be performed only by trained personnel
in a neonatal intensive care unit with fully
monitoring and resuscitation capabilities.
 Heart rate, breath rate, SpO2 and body temperature
should be monitored during ET and for 12–24 hours
after the end of the procedure.
 The most common adverse effects of ET are
thrombocytopenia, haemolysis, hypocalcaemia,
hypotension, venous thrombosis, hypokalaemia
and hypoglycaemia and should be carefully
monitored.
 Measurement of TSB should be performed before
ET and at the end of the procedure.case of haemolytic disease. Total bilirubin was plotted against age
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we recommend that TSB is measured every 4–
6 hours, and that phototherapy is continued.
 It is recommended to discontinue enteral feeding
during ET and for 6 hours from the end of the
procedure (evidence level 5).
 Infants underwent ET should be followed up for the
development of anaemia after discharge.
Other therapies
Intravenous immunoglobulins (IVIG) act by prevent-
ing haemolysis. IVIG contain pooled IgG immuno-
globulins extracted from the plasma of over 1000
blood donors. IVIG at a dose of either 500 mg/kg or 1
gr/kg over 2–4 hours reduce TSB in newborn infants with
immune haemolytic jaundice [42,43] and reduce the need
for ET (evidence level 1a). IVIG should be administered in
the first hours of life to infants with Rhesus haemolytic
disease or ABO haemolytic disease when the serum biliru-
bin continues to rise by more than 0.5 mg/dL per hour.
Italian registry of kernicterus and hyperbilirubinaemia
The Italian Society of Neonatology instituted the Italian
Registry of Kernicterus and Hyperbilirubinaemia (RIKI:
Registro Italiano del Kenicterus e dell’Iperbilirubinemia) for
monitoring the incidence of kernicterus and severe hyperbi-
lirubinaemia (TSB > 20 mg/dL or need for ET) in Italy.
Each new case can be reported through the website of the
Italian Society of Neonatology (www.neonatologia.it). The
objective of this registry is to provide evidences of the
guidelines effectiveness through the evaluation of severe
hyperbilirubinaemia and kernicterus rate.
Conclusion
The development of national guidelines provide standard-
isation of the management of neonatal jaundice. Severe
hyperbilirubinaemia in both healthy term or preterm new-
born infants continues to carry the potential for complica-
tions from ABE. The careful assessment of involved risk
factors and the systematic approach to the management
of hyperbilirubinaemia are essential to decrease the occur-
rence of kernicterus.
Additional file
Additional file 1: Exchange transfusion procedure.
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